Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma at High-Risk Recurrence

This study tests a combination of two drugs — sacituzumab govitecan (an antibody-drug conjugate that delivers chemotherapy directly to cancer cells) and nivolumab (an immunotherapy) — after surgery for muscle-invasive bladder or urinary tract cancer with a high risk of returning. **You may be eligible if...** - You are 18 or older and have confirmed muscle-invasive urothelial cancer (bladder, ureter, or kidney pelvis) - You recently had curative surgery (radical cystectomy or nephroureterectomy) within the last 6 months - Your scans show no remaining cancer after surgery - You are in good physical condition (ECOG 0–2) **You may NOT be eligible if...** - Your cancer has already spread to other organs - You have previously received certain immunotherapy drugs (PD-1/PD-L1 inhibitors) or sacituzumab govitecan before surgery - You have significant immune-related conditions or serious organ problems Talk to your doctor to see if this trial is right for you.